Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 266

1.

Two years of adjuvant tamoxifen in premenopausal patients with breast cancer: a randomised, controlled trial with long-term follow-up.

Rydén L, Jönsson PE, Chebil G, Dufmats M, Fernö M, Jirström K, Källström AC, Landberg G, Stål O, Thorstenson S, Nordenskjöld B; South Swedish Breast Cancer Group; South-East Swedish Breast Cancer Group.

Eur J Cancer. 2005 Jan;41(2):256-64.

PMID:
15661551
[PubMed - indexed for MEDLINE]
2.

HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information.

Rydén L, Landberg G, Stål O, Nordenskjöld B, Fernö M, Bendahl PO.

Breast Cancer Res Treat. 2008 May;109(2):351-7. Epub 2007 Jul 18.

PMID:
17636399
[PubMed - indexed for MEDLINE]
3.

Breast cancer patients with estrogen receptor-negative/progesterone receptor-positive tumors: being younger and getting less benefit from adjuvant tamoxifen treatment.

Yu KD, Di GH, Wu J, Lu JS, Shen KW, Liu GY, Shen ZZ, Shao ZM.

J Cancer Res Clin Oncol. 2008 Dec;134(12):1347-54. doi: 10.1007/s00432-008-0414-2. Epub 2008 May 17.

PMID:
18488249
[PubMed - indexed for MEDLINE]
4.

Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer.

Rydén L, Jirström K, Bendahl PO, Fernö M, Nordenskjöld B, Stål O, Thorstenson S, Jönsson PE, Landberg G.

J Clin Oncol. 2005 Jul 20;23(21):4695-704.

PMID:
16034044
[PubMed - indexed for MEDLINE]
Free Article
5.

Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status.

Dowsett M, Houghton J, Iden C, Salter J, Farndon J, A'Hern R, Sainsbury R, Baum M.

Ann Oncol. 2006 May;17(5):818-26. Epub 2006 Feb 23.

PMID:
16497822
[PubMed - indexed for MEDLINE]
Free Article
6.

Shorter survival-times following adjuvant endocrine therapy in oestrogen- and progesterone-receptor positive breast cancer overexpressing HER2 and/or with an increased expression of vascular endothelial growth factor.

Linderholm B, Bergqvist J, Hellborg H, Johansson U, Linderholm M, von Schoultz E, Elmberger G, Skoog L, Bergh J.

Med Oncol. 2009 Dec;26(4):480-90. doi: 10.1007/s12032-008-9157-9. Epub 2009 Jan 7.

PMID:
19130322
[PubMed - indexed for MEDLINE]
7.

High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients.

Stendahl M, Rydén L, Nordenskjöld B, Jönsson PE, Landberg G, Jirström K.

Clin Cancer Res. 2006 Aug 1;12(15):4614-8.

PMID:
16899609
[PubMed - indexed for MEDLINE]
Free Article
8.

Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer: a randomised phase III trial of the European Organisation for Research and Treatment of Cancer Breast Group.

Morales L, Canney P, Dyczka J, Rutgers E, Coleman R, Cufer T, Welnicka-Jaskiewicz M, Nortier J, Bogaerts J, Therasse P, Paridaens R; European Organisation for Research and Treatment of Cancer Breast Group; Scottish Breast Cancer Trials Group.

Eur J Cancer. 2007 Jan;43(2):331-40. Epub 2006 Nov 28.

PMID:
17134892
[PubMed - indexed for MEDLINE]
9.

Tamoxifen reduces the risk of contralateral breast cancer in premenopausal women: Results from a controlled randomised trial.

Alkner S, Bendahl PO, Fernö M, Nordenskjöld B, Rydén L; South Swedish and South-East Swedish Breast Cancer Groups.

Eur J Cancer. 2009 Sep;45(14):2496-502. doi: 10.1016/j.ejca.2009.05.022. Epub 2009 Jun 15.

PMID:
19535242
[PubMed - indexed for MEDLINE]
10.

Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93.

International Breast Cancer Study Group, Colleoni M, Gelber S, Goldhirsch A, Aebi S, Castiglione-Gertsch M, Price KN, Coates AS, Gelber RD.

J Clin Oncol. 2006 Mar 20;24(9):1332-41. Epub 2006 Feb 27.

PMID:
16505417
[PubMed - indexed for MEDLINE]
Free Article
11.

Oophorectomy and tamoxifen adjuvant therapy in premenopausal Vietnamese and Chinese women with operable breast cancer.

Love RR, Duc NB, Allred DC, Binh NC, Dinh NV, Kha NN, Thuan TV, Mohsin SK, Roanh le D, Khang HX, Tran TL, Quy TT, Thuy NV, Thé PN, Cau TT, Tung ND, Huong DT, Quang le M, Hien NN, Thuong L, Shen TZ, Xin Y, Zhang Q, Havighurst TC, Yang YF, Hillner BE, DeMets DL.

J Clin Oncol. 2002 May 15;20(10):2559-66.

PMID:
12011136
[PubMed - indexed for MEDLINE]
Free Article
12.

Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials.

Fisher B, Jeong JH, Bryant J, Anderson S, Dignam J, Fisher ER, Wolmark N; National Surgical Adjuvant Breast and Bowel Project randomised clinical trials.

Lancet. 2004 Sep 4-10;364(9437):858-68.

PMID:
15351193
[PubMed - indexed for MEDLINE]
13.

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.

Early Breast Cancer Trialists' Collaborative Group (EBCTCG).

Lancet. 2005 May 14-20;365(9472):1687-717.

PMID:
15894097
[PubMed - indexed for MEDLINE]
14.

Survival after adjuvant oophorectomy and tamoxifen in operable breast cancer in premenopausal women.

Love RR, Van Dinh N, Quy TT, Linh ND, Tung ND, Shen TZ, Hade EM, Young GS, Jarjoura D.

J Clin Oncol. 2008 Jan 10;26(2):253-7. Epub 2007 Dec 17.

PMID:
18086800
[PubMed - indexed for MEDLINE]
Free Article
15.

Progesterone receptor status provides predictive value for adjuvant endocrine therapy in older estrogen receptor-positive breast cancer patients.

Yu KD, Liu GY, Di GH, Wu J, Lu JS, Shen KW, Shen ZZ, Shao ZM.

Breast. 2007 Jun;16(3):307-15. Epub 2007 Feb 12.

PMID:
17293115
[PubMed - indexed for MEDLINE]
16.

Tamoxifen in high-risk premenopausal women with primary breast cancer receiving adjuvant chemotherapy. Report from the Danish Breast Cancer co-operative Group DBCG 82B Trial.

Andersson M, Kamby C, Jensen MB, Mouridsen H, Ejlertsen B, Dombernowsky P, Rose C, Cold S, Overgaard M, Andersen J, Kjaer M.

Eur J Cancer. 1999 Nov;35(12):1659-66.

PMID:
10674010
[PubMed - indexed for MEDLINE]
17.

Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.

Jahanzeb M.

Clin Ther. 2007 Aug;29(8):1535-47. Review.

PMID:
17919537
[PubMed - indexed for MEDLINE]
18.

Long-term survival in primary breast cancer: correlation with estrogen and progesterone receptor assay results and adjuvant tamoxifen therapy.

Chrapusta SJ, Giermek J, Pieńkowski T.

Med Sci Monit. 2004 Oct;10(10):CR577-86. Epub 2004 Sep 23.

PMID:
15448598
[PubMed - indexed for MEDLINE]
19.

Her-2/neu overexpression and response to oophorectomy plus tamoxifen adjuvant therapy in estrogen receptor-positive premenopausal women with operable breast cancer.

Love RR, Duc NB, Havighurst TC, Mohsin SK, Zhang Q, DeMets DL, Allred DC.

J Clin Oncol. 2003 Feb 1;21(3):453-7.

PMID:
12560434
[PubMed - indexed for MEDLINE]
Free Article
20.

Poor outcome of hormone receptor-positive breast cancer at very young age is due to tamoxifen resistance: nationwide survival data in Korea--a report from the Korean Breast Cancer Society.

Ahn SH, Son BH, Kim SW, Kim SI, Jeong J, Ko SS, Han W; Korean Breast Cancer Society.

J Clin Oncol. 2007 Jun 10;25(17):2360-8. Epub 2007 May 21.

PMID:
17515570
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk